APA (7th ed.) Citation

Pretta, A., Ziranu, P., Spanu, D., Lai, E., Dettori, M., Manai, C., . . . Scartozzi, M. (2022). 373P The role of concomitant RAS and BRAF mutations in influencing clinical outcome during BRAF-targeted treatment for metastatic colorectal cancer. Annals of Oncology, 33, S707. https://doi.org/10.1016/j.annonc.2022.07.511

Chicago Style (17th ed.) Citation

Pretta, A., et al. "373P The Role of Concomitant RAS and BRAF Mutations in Influencing Clinical Outcome During BRAF-targeted Treatment for Metastatic Colorectal Cancer." Annals of Oncology 33 (2022): S707. https://doi.org/10.1016/j.annonc.2022.07.511.

MLA (9th ed.) Citation

Pretta, A., et al. "373P The Role of Concomitant RAS and BRAF Mutations in Influencing Clinical Outcome During BRAF-targeted Treatment for Metastatic Colorectal Cancer." Annals of Oncology, vol. 33, 2022, p. S707, https://doi.org/10.1016/j.annonc.2022.07.511.